RxDoctor Payments Data

Bailey Croyle, PA

Medical · Phoenix, AZNPI 1578169215

Payments from drug & device makers

$3,000in general payments, 2019–2025

Across 161 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$472
  • Pfizer$388
  • Collegium Pharmaceutical, Inc.$209
  • Medtronic$120
  • Amgen$101
  • plus $553 from 16 others

What the payments were for

  • Food & beverage$3,000100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,000 in reported general payments places this provider in the 75th percentile of 748 medical providers in Arizona.

See all medical providers in Arizona

Medicare billing

Part B allowed, 2024
$84,814
Medicare patients
224
Services billed
2,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate69$47,608
Nucynta ErTapentadol Hcl19$23,898
OxycontinOxycodone Hcl28$19,376
BelbucaBuprenorphine Hcl16$15,989
Buprenorphine42$12,603
Oxycodone Hcl549$11,523
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen366$8,874
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen193$6,217
Morphine Sulfate ErMorphine Sulfate226$5,697
Fentanyl57$4,795
Hydromorphone Hcl122$2,299
Pregabalin93$1,987
Gabapentin176$1,866
Methadone Hcl60$1,698
Morphine Sulfate70$1,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Belbuca$209$87,495104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 748 medical providers in Arizona.

Other medical in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →